Answer
The safety and efficacy of Praxbind (idarucizumab) have not been established in children under 18 years.
Sources for this answer
- Praxbind 2.5 g/50 mL solution for injection/infusionBoehringer Ingelheim Limited · emc · SmPC §4.2 Posology and method of administration · Version 12Document updated
Sources checked